Liraglutide + empagliflozin combination reduced carotid intima-media thickness by 10.7%, plasma Aβ1-40 by 50.7%, and MDA by 23.7% vs insulin's 1.7%/-30.7%/-9.3% over 12 months in T2D patients.
10.7% arterial reversalGLP-1+SGLT2 combination reversed carotid wall thickening by 10.7% in 12 months — 6× more than insulin therapy
What the researchers found
12-month cIMT reduction: combo -10.7%, liraglutide -8.2%, empagliflozin -5.6%, insulin -1.7%. Aβ1-40 reduction: combo -50.7%, liraglutide -52.1%, empagliflozin -40.3%, insulin -30.7%. MDA: combo -23.7%, insulin -9.3%. cIMT regression correlated with Aβ and MDA reductions.
Why it matters
Reversing atherosclerosis — not just slowing it — is the gold standard. This shows GLP-1/SGLT2 combination achieves meaningful arterial improvement.
How the study worked
Prospective 12-month study of 183 propensity-matched T2D patients on metformin, treated with insulin, liraglutide, empagliflozin, or combination. Six-segment cIMT, plaque assessment, Aβ1-40, and MDA at baseline/6/12 months.
What this study cannot tell us
Small, single-center. Not randomized between drug classes (propensity-matched). Carotid findings may not represent coronary atherosclerosis.
How to read the evidence
Prospective propensity-matched study with serial imaging. Strong signal but not randomized.
When this study was published
Published in 2025.
The bigger picture
GLP-1 + SGLT2 combination reverses atherosclerosis more than insulin, through anti-amyloid and antioxidant mechanisms — providing vascular treatment, not just glucose management.
Questions still open
- Is plasma Aβ1-40 a useful clinical marker for atherosclerosis monitoring?
- Would the combination prevent cardiovascular events more than individual drugs?
- Should GLP-1+SGLT2 replace insulin earlier in T2D treatment?
Common questions
Can diabetes drugs reverse clogged arteries?
Why does the combination work better?
Read the original research
GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes.
American journal of physiology. Heart and circulatory physiology, 330(2), H610-H619
Citation
Ikonomidis, Ignatios; Papageorgiou, Anastasios; Pavlidis, George; Georgiopoulos, Georgios; Katogiannis, Konstantinos; Maratou, Eirini; Thymis, John; Pliouta, Loukia; Kountouri, Aikaterini; Korakas, Emmanouil; Kostelli, Gabriella; Parissis, John; Nikolaou, Panagiota Efstathia; Andreadou, Ioanna; Lambadiari, Vaia. (2026). GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes.. American journal of physiology. Heart and circulatory physiology, 330(2), H610-H619. https://doi.org/10.1152/ajpheart.00996.2025